The role of Mycoplasma pneumoniae in acute and chronic asthma remains elusive;however, multiple lines of evidence linking Mycoplasma to chronic asthma, exacerbations of asthma, and long-term decrements In pulmonary function suggest this organism may play an important role in asthma. The diagnosis of M. pneumoniae infection, however, is difficult because M. pneumoniae is a fastidious organism, capable of extracellular and intracellular parasitism/persistence, and therefore, microbiological growth directly from clinical specimens almost always fails. The diagnosis of active M. pneumoniae becomes even more difficult in states of chronic carriage where organism burdens would be significantly lower. Recently, our group identified a M. pneumoniae ADP-ribosylating/vacuolating toxin known as the Community Acquired Respiratory Distress Syndrome Toxin (CARDS TX) and created a PCR probe (MPN372) specific for amplifying cards gene sequences. In a recent outbreak of Mycoplasma community-acquired pneumonia, the Centers for Disease Control and Prevention demonstrated that PCR to CARDS TX was the most sensitive assay tested. A major barrier for understanding the role of M. pneumoniae in asthma has been the relative absence of a sensitive method to detect M. pneumoniae and a failure to understand the specific immunomodulatory role of M. pneumoniae infection. Using sensitive PCR and antigen capture assays to detect CARDS TX, we have been able to demonstrate that 43.6% of adult subjects with acute exacerbations of asthma are positive to MPN372 by real-time PCR versus 11% of subjects admitted with non-asthmatic lung disease and 4% in normal healthy controls (p<.001 for acute asthma vs controls). Additionally, we have established a clinical research site to follow subjects with refractory asthma and found 30/62 subjects (48%) were PCR positive for CARDS TX, with 10% remaining persistently positive over a mean period of 10.3 months. Two thirds of these persistently positive subjects never mounted an IgG response to Mycoplasma (ELISA to either CARDS TX or PI adhesin). The Clinical Core will undertake a longitudinal study to collect samples on both CARDS TX +/- asthmatics as well as CARDS TX +/- healthy controls to establish the role of M. pneumoniae in asthma severity and control as well as the differences in the immunologic responses to M. pneumoniae in asthmatic subjects compared to healthy non-asthmatic controls.

Public Health Relevance

The findings in this study will have a significant impact on our understanding of how M. pneumoniae impacts asthma severity and control. Since 10% of refractory asthmatics may be chronically infected with M. pneumoniae, interventions to eliminate M. pneumoniae or CARDS TX produced by M. pneumoniae has significant therapeutic implications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI070412-08
Application #
8513883
Study Section
Special Emphasis Panel (ZAI1-PA-I)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
8
Fiscal Year
2013
Total Cost
$267,273
Indirect Cost
$66,348
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Ji, Hong; Zhang, Xue; Oh, Sunghee et al. (2015) Dynamic transcriptional and epigenomic reprogramming from pediatric nasal epithelial cells to induced pluripotent stem cells. J Allergy Clin Immunol 135:236-44
Medina, Jorge L; Coalson, Jacqueline J; Brooks, Edward G et al. (2014) Mycoplasma pneumoniae CARDS toxin exacerbates ovalbumin-induced asthma-like inflammation in BALB/c mice. PLoS One 9:e102613
Kannan, Thirumalai R; Krishnan, Manickam; Ramasamy, Kumaraguruparan et al. (2014) Functional mapping of community-acquired respiratory distress syndrome (CARDS) toxin of Mycoplasma pneumoniae defines regions with ADP-ribosyltransferase, vacuolating and receptor-binding activities. Mol Microbiol 93:568-81
Somarajan, Sudha R; Al-Asadi, Fadi; Ramasamy, Kumaraguruparan et al. (2014) Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells. MBio 5:
Burks, Margaret L; Brooks, Edward G; Hill, Vanessa L et al. (2013) Assessing proxy reports: agreement between children with asthma and their caregivers on quality of life. Ann Allergy Asthma Immunol 111:14-9
Krishnan, Manickam; Kannan, T R; Baseman, Joel B (2013) Mycoplasma pneumoniae CARDS toxin is internalized via clathrin-mediated endocytosis. PLoS One 8:e62706
Kannan, T R; Hardy, R D; Coalson, J J et al. (2012) Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis 54:225-31
Medina, Jorge L; Coalson, Jacqueline J; Brooks, Edward G et al. (2012) Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol 46:815-22
Johnson, Coreen; Kannan, T R; Baseman, Joel B (2011) Cellular vacuoles induced by Mycoplasma pneumoniae CARDS toxin originate from Rab9-associated compartments. PLoS One 6:e22877
Muir, Mark T; Cohn, Stephen M; Louden, Christopher et al. (2011) Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest 139:305-10

Showing the most recent 10 out of 20 publications